DEF 14A: Spruce Biosciences Proposes Reverse Stock Split to Regain Nasdaq Compliance
Proxy Statement
Spruce Biosciences seeks stockholder approval for a reverse stock split to meet Nasdaq's minimum bid price requirement and facilitate future financing.
Summary
- Spruce Biosciences has announced its 2025 Annual Meeting of Stockholders to be held virtually on June 9, 2025.
- The meeting will address the election of three Class II directors, ratification of the independent accounting firm, a proposed reverse stock split, and approval for adjournment if necessary.
- A key proposal is to approve an amendment to the company's charter to effect a reverse stock split of its common stock at a ratio between 1-for-5 and 1-for-30, determined by the Board.
- The company aims to regain compliance with Nasdaq's minimum bid price requirement, which it failed to meet, leading to a delisting notice.
- The Board believes a higher stock price could attract a broader range of investors and improve the perception of the stock.
- The company's cash and cash equivalents of $38.8 million as of December 31, 2024, are insufficient to fund planned operations and debt obligations for the next 12 months.
- The company needs to raise additional capital, and the reverse stock split is seen as a way to facilitate this.
- The company is exploring various sources of financing, including potential future sales of common stock or other securities.
- The reverse stock split alone would have no effect on the authorized capital stock, and the total number of authorized shares would remain the same as before the reverse stock split.
- The Board reserves the right to abandon the reverse stock split if it's no longer in the company's best interest.
- The company is also seeking approval to adjourn the Annual Meeting if there are insufficient votes for the reverse stock split proposal.
Sentiment
Score: 4
Explanation: The document presents a mixed outlook. While the company is taking steps to address its Nasdaq compliance issues and secure future financing, the delisting notice and concerns about its ability to continue as a going concern weigh negatively on the sentiment.
Positives
- A reverse stock split could make the company's stock more attractive to a broader range of investors, including institutional investors.
- A higher stock price may improve the perception of the company's stock as a viable investment security.
- Increasing the number of available shares for issuance could provide flexibility for future financings and strategic transactions.
- The Board retains the flexibility to abandon the reverse stock split if it's no longer in the company's best interest.
Negatives
- The reverse stock split may not result in a lasting increase in the per-share price of the company's common stock.
- The company cannot guarantee that it will meet the requirements to regain listing on Nasdaq.
- The reverse stock split could reduce the number of outstanding shares while increasing the number of authorized but unissued shares, potentially having anti-takeover implications.
- If the reverse stock split is effected and the market price of the common stock declines, the percentage decline as an absolute number and as a percentage of the overall market capitalization of the Company may be greater than would occur in the absence of the Reverse Stock Split.
Risks
- The company's ability to continue as a going concern is dependent on raising additional capital.
- There is no assurance that additional financing will be available or on terms acceptable to the company.
- Failure to regain compliance with Nasdaq listing requirements could result in delisting and reduced trading activity.
- The reverse stock split may not attract brokers and investors who do not trade in lower-priced stocks.
- The reverse stock split may have anti-takeover implications.
Future Outlook
The company's future is dependent on raising additional capital and regaining compliance with Nasdaq listing requirements. The company is exploring various sources of financing, including potential future sales of common stock or other securities.
Industry Context
Reverse stock splits are a common strategy for companies facing delisting from major exchanges due to low stock prices. The success of such splits varies, and the company's ability to execute its business plan and achieve milestones will ultimately determine its long-term value.
Comparison to Industry Standards
- Many biotechnology companies facing similar challenges have implemented reverse stock splits to maintain exchange listing.
- Comparable companies include those that have received delisting notices from Nasdaq and subsequently pursued reverse stock splits to regain compliance.
- The success of these strategies depends on various factors, including market conditions, investor sentiment, and the company's ability to achieve its clinical and financial goals.
- For example, some companies have successfully regained compliance and maintained their listing, while others have continued to struggle despite the reverse stock split.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Chief Medical Officer | Ralph William Charlton III, M.D., M.A.S. | NA | December 31, 2024 | Dr. Charlton ceased employment with the company. |
Related Party Transactions
- Certain holders of more than 5% of the company's capital stock, including those affiliated with members of the Board, purchased shares of the company's common stock in the Private Placement at the offering price offered to other investors.
Stakeholder Impact
- Shareholders: Potential dilution from future stock issuances, impact on stock price depending on the success of the reverse stock split and financing efforts.
- Employees: Job security dependent on the company's ability to secure financing and continue operations.
- Customers: Continued access to the company's therapies dependent on the company's financial stability.
Next Steps
- Stockholder vote on the proposed reverse stock split and other proposals at the Annual Meeting on June 9, 2025.
- Board determination on whether to implement the reverse stock split and the specific ratio.
- Filing of the Certificate of Amendment with the Secretary of State of the State of Delaware if the reverse stock split is approved.
- Continued efforts to secure additional financing to fund operations.
Key Dates
| Date | Description |
|---|---|
| April 7, 2016 | Original certificate of incorporation filed with the Secretary of State of the State of Delaware |
| October 14, 2020 | Amended certificate of incorporation filed with the Secretary of State of the State of Delaware |
| April 26, 2024 | Company received a deficiency letter from Nasdaq regarding the minimum bid price requirement. |
| October 24, 2024 | Company received notification from Nasdaq approving the application to list its stock on the Nasdaq Capital Market. |
| October 28, 2024 | Company's securities were transferred to the Nasdaq Capital Market. |
| December 31, 2024 | Ralph William Charlton III, M.D., M.A.S., former Chief Medical Officer ceased employment with the company. |
| April 1, 2025 | Ownership Measurement Date for beneficial ownership of common stock. |
| April 10, 2025 | Record date for the Annual Meeting. |
| April 21, 2025 | End of the additional 180 calendar day period to regain compliance with the Bid Price Rule. |
| April 22, 2025 | Company received a written notification from Nasdaq that as a result of the Company’s ongoing failure to comply with the Bid Price Rule, the Company’s common stock will be delisted from Nasdaq. |
| April 28, 2025 | Proxy materials are being distributed and made available on or about this date. |
| April 29, 2025 | Expected date for the company's common stock to begin trading publicly on the over-the-counter market. |
| June 8, 2025 | Deadline to vote by telephone or internet (11:59 p.m. Eastern Time). |
| June 9, 2025 | Annual Meeting of Stockholders at 10:00 a.m. (Pacific Time). |
| December 16, 2025 | Deadline for stockholders to submit proposals for inclusion in next year's proxy materials. |
| February 9, 2026 | Start of the period for stockholders to submit proposals (including director nominations) at the meeting that are not to be included in next year's proxy materials. |
| March 11, 2026 | End of the period for stockholders to submit proposals (including director nominations) at the meeting that are not to be included in next year's proxy materials. |
Keywords
reverse stock split, Nasdaq, compliance, financing, delisting, proxy statement, annual meeting, stockholders, capital, shares
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.